Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2010, Article ID 736907, 10 pages
Research Article

Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68

1Genelux Corporation, San Diego Science Center, San Diego, CA 92109, USA
2Department of Biochemistry, University of Wuerzburg, 97074 Wuerzburg, Germany
3Center for Human Genetics, University of Bremen, 28359 Bremen, Germany
4Small Animal Clinic, University of Veterinary Medicine, Bischofsholer Damm 15, 30173 Hannover, Germany
5Rudolf Virchow Center for Experimental Biomedicine, University of Wuerzburg, 97078 Wuerzburg, Germany
6Institute for Molecular Infection Biology, University of Wuerzburg, 97078 Wuerzburg, Germany
7Department of Radiation Oncology, Moores Cancer Center, University of California, San Diego, 3855 Health Sciences Drive 0843, La Jolla, CA 92093-0843, USA

Received 28 August 2009; Revised 18 February 2010; Accepted 11 May 2010

Academic Editor: Dominic Fan

Copyright © 2010 Ivaylo Gentschev et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Canine mammary carcinoma is a highly metastatic tumor that is poorly responsive to available treatment. Therefore, there is an urgent need to identify novel agents for therapy of this disease. Recently, we reported that the oncolytic vaccinia virus GLV-1h68 could be a useful tool for therapy of canine mammary adenoma in vivo. In this study we analyzed the therapeutic effect of GLV-1h68 against canine mammary carcinoma. Cell culture data demonstrated that GLV-1h68 efficiently infected and destroyed cells of the mammary carcinoma cell line MTH52c. Furthermore, after systemic administration, this attenuated vaccinia virus strain primarily replicated in canine tumor xenografts in nude mice. Finally, infection with GLV-1h68 led to strong inflammatory and oncolytic effects resulting in significant growth inhibition of the tumors. In summary, the data showed that the GLV-1h68 virus strain has promising potential for effective treatment of canine mammary carcinoma.